Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan Yoon as General Counsel and Chief Administrative Officer, and Aditya Venugopal as Chief Business Officer. Mr. Yoon and Dr. Venugopal are joining Alentis’ executive leadership team.

“We are expanding our corporate capabilities as we gear up for significant near-term inflection points, with key clinical data readouts in our fibrosis and oncology programs expected next year,” said Dr. Mark Pruzanski, CEO of Alentis . “It is terrific to be working again with Bryan and Aditya whose knowledge and experience will be of great value to the team and the company’s prospects.”

Br

See Full Page